Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

105.68 +1.65 (+1.59%)
Official Closing Price Updated: 7:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,920,401
Open 103.70
Bid (Size) 104.83 (2)
Ask (Size) 105.79 (1)
Prev. Close 104.03
Today's Range 103.56 - 105.93
52wk Range 72.88 - 115.49
Shares Outstanding 2,531,374,696
Dividend Yield 2.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
 
Via Benzinga
The 7 Most Undervalued Blue-Chip Stocks to Buy in February 2023
If you're looking for undervalued blue-chip stocks, we've come up with a list of seven stocks that you can consider adding. 
Via InvestorPlace

Performance

YTD
-4.91%
-4.91%
1 Month
-4.26%
-4.26%
3 Month
+4.12%
+4.12%
6 Month
+18.05%
+18.05%
1 Year
+36.22%
+36.22%

More News

Read More
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
Via Investor's Business Daily
Merck (MRK) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Merck Beats Earnings Estimates
Via Talk Markets
Merck's 2023 Earnings Guidance Widely Missed; Shares Slide
Via Investor's Business Daily
Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023
Via Benzinga
Why Personalis Shares Are Trading Higher Today
Via Benzinga
Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients
Via Benzinga
Merck's Oral COVID-19 Treatment Might Be Linked To Spreading Mutations, Study Shows
Via Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck & Co Earnings Preview
Via Benzinga
Checking In With Merck Stock Before Earnings
Via Talk Markets
The 7 Most Undervalued Dow Stocks to Buy in February 2023
Via InvestorPlace
Why These 2 Stocks Made the Dow Miss the Market Rally
Via The Motley Fool
US Stocks Higher, NASDAQ Adds Over 230 Points
Via Benzinga
Got $5,000? 3 Stocks to Hold for the Next 20 Years
Via The Motley Fool
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Via Benzinga
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
7 Healthcare Stocks That Will Be Big Winners in 2023
Via InvestorPlace
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Via Talk Markets
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Via The Motley Fool
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.